Atlas Trials

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Clinical trial NCT05705466 · WITHDRAWN

Trial details

NCT number
NCT05705466
Sponsor
Kartos Therapeutics, Inc.
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2023-06-01
Primary completion
2025-06-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.